Open an account

IRadimed

IRMD · NASDAQ

$88.24+$0.59 (+0.67%)TodayMarket closed ·
Prev close $87.65

About IRMD

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. The company is headquartered in Orlando, Florida and currently employs 166 full-time employees. The company went IPO on 2014-07-16. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The firm sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.

Employees
166
Headquarters
Orlando, Florida
Listed
Jul 16, 2014
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
iradimed.com

IRMD key statistics

Market cap
1.13B
Price-earnings ratio
48.97
Dividend yield
1.41%
Average volume
122.01K
Volume
83.01K
Open price
$88.30
High today
$89.43
Low today
$87.69
52 Week high
$107.90
52 Week low
$73.25

IRadimed (IRMD) at a glance

As of Oct 20, 2026, IRadimed (IRMD) shares are priced at $88.24, giving the company a market cap of 1.13B, a price-to-earnings ratio of 48.97 and a dividend yield of 1.41%.

Today the stock has traded between $87.69 and $89.43. The current price is 0.6% above the day's low and 1.3% below its high.

Volume so far is 83.01K shares, below the average of 122.01K shares a day.

Over the past year IRadimed has ranged from $73.25 to $107.90, and now sits 43% of the way up that range.

IRadimed met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.46 per share against an estimate of $0.4284.

The average analyst price target is $120.36, 36.4% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $120.36
Low
$117.16
Now
$88.24
High
$126.00

IRMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 6.8% on average.

  1. Q3 FY24: reported $0.43 per share against an estimate of $0.3927
  2. Q4 FY24: reported $0.44 per share against an estimate of $0.4488
  3. Q1 FY25: reported $0.42 per share against an estimate of $0.4182
  4. Q2 FY25: reported $0.49 per share against an estimate of $0.4437
  5. Q3 FY25: reported $0.47 per share against an estimate of $0.4641
  6. Q4 FY25: reported $0.54 per share against an estimate of $0.4896
  7. Q1 FY26: reported $0.49 per share against an estimate of $0.4539
  8. Q2 FY26: reported $0.46 per share against an estimate of $0.4284

IRMD news

  • Shomik Sen Bhattacharjee

    Elon Musk Confirms Starlink Can Deliver Reliable 10 Gigabit-a-Second Upload and Download Speeds Anywhere On Earth

Similar companies

Companies in the same industry as IRadimed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.